AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2011

Mar 3, 2011

30291_dirs_2011-03-03_e77d01c4-14ed-4dd7-9cd9-10bd3c751956.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2011-03-02

Reporting Person: Cox John (EVP Pharmaceutical Oper & Tech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-03-02	Common Stock	S	1458	$70.1059	Disposed	12401.0411	Direct
2011-03-02	Common Stock	S	2483	$70.0762	Disposed	9918.0411	Direct
2011-03-02	Common Stock	S	100	$70.45	Disposed	9818.0411	Direct

Footnotes

F1: This represents the weighted average price for shares sold at a range between $69.57 (low) and $70.41 (high).

F2: This represents the weighted average price for shares sold at a range between $69.44 (low) and $70.40 (high).

F3: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.